Professor Oliver Bandmann MD PhD

Professor of Clinical Neurology
Honorary Consultant Neurologist

Oliver Bandmann image

Department of Neuroscience
Sheffield Institute of Translational Neuroscience
University of Sheffield
Room B32
385a Glossop Road
Sheffield
S10 2HQ

Telephone: +44 (0) 114 2222237
Fax: +44 (0)114 2222290
Email: o.bandmann@sheffield.ac.uk

NHS Secretary: Marilyn Bestall
Telephone: +44 (0)114 271 3005
Email: marilyn.bestall@sth.nhs.uk

Academic Secretary: Rebecca Brown
Tel: 0114 2222261
Email:rebecca.brown@sheffield.ac.uk

Career History

2002-present: Senior Lecturer in Neurology, University of Sheffield;
1997-2002: Specialist Training in Neurology, Marburg, Germany;
1993-1997: Research Fellow, Institute of Neurology. Queen Square London. PhD on "Genetic Aspects of Parkinsonian Disorders" (Supervisors: Prof A.E. Harding, Prof C.D. Marsden, Prof N.W. Wood)
1992-1993: House officer, Dept Neurology, Klinikum Grosshadern, Munich (Head: Prof T. Brandt)
1991: Qualification at Ludwig Maximilian´s University Munich, Germany

Research

My research focuses on different aspects of basal ganglia disorders such as Parkinson´s Disease, Huntington´s Disease, Wilson Disease or dystonia.

Recently finished or currently ongoing projects:

1.Parkinson´s Disease (PD):
1.1. We have just completed a genetic research project investigating different genes and genetic loci for a possible role as either susceptibility factors for PD or disease-modifying factors, i.e. determining the age of onset.
1.2. I have collaborated on the investigation of dopamine receptor gene polymorphisms as risk factors for "sleep attacks" in PD (Rissling et al., 2004).
1.3. We have established the first zebrafish model of familial PD worldwide (Bretaud et al., 2007) and continue to use this new vertebrate animal model for studies which will hopefully lead to a better understanding of the different mechanisms leading to neuronal cell death in human patients.
1.4. We are currently also investigating the effect of PD gene mutations on mitochondrial function in a new cell culture system.

Our main future goal is to use both our new cell culture system and the zebrafish model to identify new, disease-modifying therapy for PD.

2. Huntington´s Disease (HD)
2.1. Together with Dr Quarrell (consultant geneticist) and Katherine Tidswell (neuropsychology assistant) we are currently involved in the EURO-HD REGISTRY study. The aim of this study is to obtain a better understanding of the natural course of HD.
2.2. I am also participating in a drug trial investigating a new drug, Amarin, for its possible effect on chorea.
2.3. We will be part of the HD network of the Dementias and Neurodegenerative Diseases Research Network. (DeNDRoN)

3. Wilson Disease (WD)
2.1. I have contributed to the development of the first validated clinical rating scale for the neurological impairment in WD (EURO-WILSON collaboration, Czlonkowska et al., 2007).
2.2. I have contributed to a recently published study investigating the role of the common H1069Q mutation of ATP7B as a disease-modifying factor for PD (Moeller et al., 2006).
2.3. We are currently determining the genetic prevalence of WD by screening a very large number of normal controls for common WD mutations (collaboration with the Welcome Sanger Institute, Cambridge, UK).
2.4. We are also involved in the systematic assessment of the mutation distribution and frequency of ATP7B mutations in UK patients with WD (collaboration with Dr M Sayer and Dr A Dalton, Genetics Service Laboratory, Children´s Hospital, Sheffield).

4. Dystonia
4.1. We have recently published a study investigating a possible role of torsinA haplotypes as susceptibility factors for sporadic adult-onset dystonia (Hague et al., 2006).
4.2. We are currently undertaking a detailed study of dopa-responsive dystonia in the UK.
4.3. I also continue to be involved as the PI in gene expression studies in a new toxin-induced animal model of dystonia (collaboration with Dr Alvarez-Fischer, Paris, France and Prof W.H Oertel, Marburg, Germany).

5. Other projects
Other, currently ongoing or recently completed studies undertaken directly by my group and additional studies I have been involved with as a collaborator are listed below:
5.1. Linkage analysis in familial Bell´s palsy (ongoing)
5.2. Candidate gene studies in Gilles de la Tourette syndrome (Klaffke et al., 2006; Asmus et al., 2005).
5.3. Central nervous system involvement in hereditary neuropathy with liability to pressure palsies (HNPP, Tackenberg et al., 2006).
5.4. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy (Kamm et al., 2005).

Esteem Factors

1984-1991: Bavarian Scholarship for highly gifted students
1986-1991: German Scholarship for highly gifted students ("Studienstiftung des Deutschen Volkes")
1993-1997: Training Fellowship of Deutsche Forschungsgemeinschaft (DFG)
1996: President´s Prize of Royal Society of Medicine
1997: Queen Square Prize of Institute of Neurology
2000: Oppenheim Prize of German Dystonia Society
2006: "Consultant Teacher of the Year" Prize of "Med Soc" (organization of medical students at UoS Medical School)

Member of the Editorial Board of the clinical Neuroscience Journal NEUROLOGY

President of the Doncaster Branch of the Parkinson´s Disease Society, UK

Member of the regional PDS advisory board for Yorkshire and Humberside

Principal Funding Sources (current and recent)

1. Parkinson´s Disease Society (PDS):"Disease-modifying factors in Parkinson´s Disease" (£ 43,174,-)

2. Help the Aged – Research into Ageing: A LRRK2 mutant zebrafish model of Parkinson´s Disease (£ 49,530,-)

3. UoS Sheila McKenzie Fund: "The influence of the genetic background on zebrafish motility and susceptibility to neurotoxins" (£ 40,700,-)

4. Parkinson´s Disease Society (PDS): "A PINK1 mutant zebrafish model of Parkinson´s Disease (£99,359,-)

5. Michael J Fox Foundation, USA: A DJ-1 mutant zebrafish model of Parkinson´s Disease (£ 103,000,-)

6. Sheffield Hospitals Charitable Trust: A Clinical and genetic study of Wilson Disease (£ 48,900,-)

7. Huntington´s Disease Association (HDA): EURO-HD Registry study
(£ 30,000,-)

8. The Dementias and Neurodegenerative Diseases Research Network. (DeNDRoN)

Members of Research Group

  • Dr S Bretaud, Dr L Flinn, Dr H Mortiboys (all postdoctoral scientists)
  • A Ludo Radillo (PhD student)
  • Christine Lo (BMedSci student)
  • Sarah Russell (technician)

Representative Publications (last 5 years)

Bretaud-Marsollier S, Allen CE, Ingham PW, Bandmann O (2007): p53 dependent neuronal cell death in a DJ-1 deficient zebrafish model of Parkinson´s disease. J Neurochem 100:1626-1635.

Tackenberg B, Moeller JC, Rindock H, Bien S, Sommer N, Oertel WH, Rosenow F, Schepelmann K, Hamer HM, Bandmann O (2006): CNS involvement in Hereditary Neuropathy with Pressure Palsies (HNPP). Neurology 67:2250-2.

Hague S, Klaffke S, Clarimon J, Hemmer B, Singleton A, Kupsch A, Bandmann O (2006): Lack of association with TorsinA haplotype in German patients with sporadic dystonia. Neurology 66:951-952.

Klaffke S, Konig IR, Poustka F, Ziegler A, Hebebrand J, Bandmann O (2006): Brain-derived neurotrophic factor: a genetic risk factor for obsessive-compulsive disorder and Tourette syndrome? Mov Disord 881-883.

Kamm C, Healy DG, Quinn NP, Wullner U, Moller JC, Schols L, Geser F, Burk K, Borglum AD, Pellecchia MT, Tolosa E, del Sorbo F, Nilsson C, Bandmann O, Sharma M, Mayer P, Gasteiger M, Haworth A, Ozawa T, Lees AJ, Short J, Giunti P, Holinski-Feder E, Illig T, Wichmann HE, Wenning GK, Wood NW, Gasser T (2005): The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA study group. Brain 128:1855-1860.

Bandmann O (2004): DJ-1: the second gene for early onset Parkinson disease. Neurology 62:357-8.

Grundmann M, Earl CD, Sautter J, Henze C, Oertel WH, Bandmann O (2003): Slow N-acetyltransferase 2 status leads to enhanced intrastriatal dopamine depletion in 6-hydroxydopamine-lesioned rats. Exp Neurol 187:199-202.

Sibbing D, Asmus F, Konig IR, Tezenas du Montcel S, Vidailhet M, Sangla S, Oertel WH, Brice A, Ziegler A, Gasser T, Bandmann O (2003): Candidate gene studies in focal dystonia. Neurology 61:1097-101.

Schoenian S, Koenig I, Oertel W, Remschmidt H, Ziegler A, Hebebrandt J, Bandmann O (2003): HLA-DRB genotyping in Gilles de la Tourette patients and their parents. Am J Med Genet 119:60-4.

Bandmann O, Goertz M, Zschocke J, Deuschl G, Jost W, Hefter H, Muller U, Zofel P, Hoffmann G, Oertel WH (2003): The phenylalanine loading test in the differential diagnosis of dystonia. Neurology 60:700-702.